CLDN18.2 in pancreatic ductal adenocarcinoma: Biomarker assessment, spatial heterogeneity and therapeutic modality selection
- 1Department of Oncology The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang PR China
- 2Department of Surgery, Clinical Sciences Lund Lund University, Skåne University Hospital Lund Sweden
Abstract
Background Claudin 18.2 (CLDN18.2) is expressed in a subset of pancreatic ductal adenocarcinomas (PDACs) and is under clinical development as a target for monoclonal antibodies, antibody‐drug conjugates, immune‐cell engagers, and chimeric antigen receptor (CAR) T‐cell therapies. The testing and clinical‐development pathways established in gastric and gastroesophageal junction cancers provide a useful reference for PDAC; however, PDAC studies have yet to standardize the antibodies, specimen types, scoring methods, or positivity thresholds used for patient selection. Intratumoral and interlesional heterogeneity, discordance between primary and metastatic sites, and changes in membrane localization limit the ability of a single positive or negative sample to capture the tumor's antigenic state. Therapeutic modalities also differ in their requirements for membrane‐antigen coverage, spatial distribution, and the tumor microenvironment. Methods This narrative review draws on peer‐reviewed articles, regulatory documents, ClinicalTrials.gov records, and relevant conference abstracts available through 31 July 2026. This review examines the biological basis, pathological assessment, spatial heterogeneity, and therapeutic development of CLDN18.2 in PDAC, with particular emphasis on treatment selection across different expression states. Results At baseline, the percentage of tumor cells with 2+/3+ membranous staining is used to describe antigen coverage, H‐score complements this measure by capturing overall expression, and intratumoral and interlesional distribution and specimen representativeness are recorded separately. Conclusion These findings support the selection of monoclonal antibodies, antibody‐drug conjugates, immune‐cell engagers, and CAR T‐cell therapy according to antigen coverage and spatial distribution, as well as treatment sequencing after disease progression.
Related
- Disulfidptosis-related genes stratify molecular subtypes and highlight MYH9 as a prognostic biomarker and candidate therapeutic target in pancreatic ductal adenocarcinoma
- Myeloid-driven immunosuppression as a context-dependent therapeutic bottleneck in pancreatic ductal adenocarcinoma
- An intron retention-derived secreted Endoglin Isoform as a circulating biomarker in pancreatic ductal adenocarcinoma.
- Non-Invasive Assessment of SMAD4 Expression Status in Pancreatic Ductal Adenocarcinoma: Diagnostic Value of T1ρ-Weighted Imaging Combined with Clinical Parameters
- Machine learning models integrating 2D and 3D intratumoral heterogeneity features from multi-sequence MRI: accurate prediction of perineural invasion in pancreatic ductal adenocarcinoma
BibTeX
@article{tan2026cldn182,
title = {{CLDN18.2 in pancreatic ductal adenocarcinoma: Biomarker assessment, spatial heterogeneity and therapeutic modality selection}},
author = {Ruyu Tan and Zhexin Zhang and Jiaxin Wang and Roland Andersson and Daniel Ansari and Jinfei Chen},
journal = {Clinical and Translational Discovery},
year = {2026},
month = oct,
doi = {10.1002/ctd2.70202},
url = {https://doi.org/10.1002/ctd2.70202},
note = {CC BY},
}
RIS
TY - JOUR
TI - CLDN18.2 in pancreatic ductal adenocarcinoma: Biomarker assessment, spatial heterogeneity and therapeutic modality selection
AU - Ruyu Tan
AU - Zhexin Zhang
AU - Jiaxin Wang
AU - Roland Andersson
AU - Daniel Ansari
AU - Jinfei Chen
PY - 2026
DA - 2026/10/26
JO - Clinical and Translational Discovery
DO - 10.1002/ctd2.70202
UR - https://doi.org/10.1002/ctd2.70202
AB - Background Claudin 18.2 (CLDN18.2) is expressed in a subset of pancreatic ductal adenocarcinomas (PDACs) and is under clinical development as a target for monoclonal antibodies, antibody‐drug conjugates, immune‐cell engagers, and chimeric antigen receptor (CAR) T‐cell therapies. The testing and clinical‐development pathways established in gastric and gastroesophageal junction cancers provide a useful reference for PDAC; however, PDAC studies have yet to standardize the antibodies, specimen types, scoring methods, or positivity thresholds used for patient selection. Intratumoral and interlesional heterogeneity, discordance between primary and metastatic sites, and changes in membrane localization limit the ability of a single positive or negative sample to capture the tumor's antigenic state. Therapeutic modalities also differ in their requirements for membrane‐antigen coverage, spatial distribution, and the tumor microenvironment. Methods This narrative review draws on peer‐reviewed articles, regulatory documents, ClinicalTrials.gov records, and relevant conference abstracts available through 31 July 2026. This review examines the biological basis, pathological assessment, spatial heterogeneity, and therapeutic development of CLDN18.2 in PDAC, with particular emphasis on treatment selection across different expression states. Results At baseline, the percentage of tumor cells with 2+/3+ membranous staining is used to describe antigen coverage, H‐score complements this measure by capturing overall expression, and intratumoral and interlesional distribution and specimen representativeness are recorded separately. Conclusion These findings support the selection of monoclonal antibodies, antibody‐drug conjugates, immune‐cell engagers, and CAR T‐cell therapy according to antigen coverage and spatial distribution, as well as treatment sequencing after disease progression.
SN - 2768-0622
ER -